{"collection_id":"htan_ohsu","collection_name":"HTAN-OHSU","cancer_types":"Breast Cancer","tumor_locations":"Breast","species":"Human","subjects":1,"supporting_data":null,"description":"The overall goal of the HTAN OMS Atlas Center is to elucidate mechanisms by which metastatic breast\ncancers become resistant to current generation pathway- and immune checkpoint-targeted treatments.\nThe OMS Atlas is motivated by the appreciation that these treatments are often effective in primary\ntumors but only transiently effective in the metastatic setting. Possible resistance mechanisms\ninclude tumor-intrinsic genomic instability and epigenomic plasticity, as well as events extrinsic\nto the cancer cells, including chemical and mechanical signals from the microenvironments,\nproduction of mechanical extracellular matrix barriers and/or changes in vasculature that reduce\ndrug and/or immune cell access, nanoscale cancer cell-microenvironment interactions that reduce drug\nefficacy, and a plethora of immune resistance mechanisms, such as loss of HLA expression and antigen\npresentation, and immune exhaustion. These mechanisms likely vary between patients and within\nindividual patients and change with time as tumors respond to therapeutic attack. The OMS Atlas will\nfocus on elucidating resistance mechanisms in two specific current generation clinical trial\nscenarios: (a) hormone receptor-positive breast cancer (HRBC) undergoing treatment with a CDK4/6\ninhibitor in combination with endocrine therapy and (b) triple negative breast cancer (TNBC)\nundergoing treatment with a PARP inhibitor and an immunomodulatory agent.\nPlease see the\n DICOM converted Slide Microscopy images for the HTAN-OHSU collection (https://doi.org/10.5281/zenodo.12689950)\n information page to learn more about the images\nand to\nobtain any supporting metadata for this collection.","patients":1,"studies":1,"series":74,"instances":5703,"size_TB":0.332,"modalities":["PR","SM"],"licenses":[{"license_short_name":"CC BY 4.0","series":74,"size_TB":0.332}]}